{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:46:15Z","timestamp":1780343175354,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.pupt.2018.10.005","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T22:53:14Z","timestamp":1540075994000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2329-5895","authenticated-orcid":false,"given":"Roberto","family":"Dal Negro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6884-3766","authenticated-orcid":false,"given":"Silvano G.","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"116","key":"10.1016\/j.pupt.2018.10.005_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1183\/09059180.00003510","article-title":"Mucoactive drugs","volume":"19","author":"Balsamo","year":"2010","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.pupt.2018.10.005_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.pharmthera.2008.11.001","article-title":"Airway mucus: the good, the bad, the sticky","volume":"121","author":"Evans","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2018.10.005_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1378\/chest.08-0412","article-title":"Mucins , mucus, and sputum","volume":"135","author":"Voynow","year":"2009","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.pupt.2018.10.005_bib4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0169-409X(02)00156-4","article-title":"Pharmacological approaches to discovery and development of new mucolytic agents","volume":"54","author":"King","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.pupt.2018.10.005_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/07853890600585795","article-title":"Treatment of airway mucus hypersecretion","volume":"38","author":"Rogers","year":"2006","journal-title":"Ann. Med."},{"key":"10.1016\/j.pupt.2018.10.005_bib6","series-title":"Therapy for Mucus Clearance Disorders","year":"2004"},{"key":"10.1016\/j.pupt.2018.10.005_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/15412555.2017.1347918","article-title":"Impact of mucolytic agents on COPD. Exacerbations: a pair-wise and network meta-analysis","author":"Cazzola","year":"2017","journal-title":"COPD"},{"issue":"2","key":"10.1016\/j.pupt.2018.10.005_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.2042-7158.1990.tb05357.x","article-title":"Model systems for the evaluation of mucolytic drugs: acetylcysteine and S-carboxymethylcysteine","volume":"42","author":"Livingstone","year":"1990","journal-title":"J. Pharm. Pharmacol."},{"issue":"3","key":"10.1016\/j.pupt.2018.10.005_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/17476348.1.3.307","article-title":"Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease","volume":"1","author":"Moretti","year":"2007","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.pupt.2018.10.005_bib10","first-page":"323","article-title":"Efficacy and safety of erdosteine in the treatment of chronic rhinosinusitis with nasal polyposis \u2013 a pilot study","volume":"51","author":"Hoza","year":"2013","journal-title":"Rhynology"},{"key":"10.1016\/j.pupt.2018.10.005_bib11","first-page":"117","article-title":"Erdostein u otitis media secretorica [Erdosteine in otitis media secretoria] Otorinolaryng","volume":"110","author":"Otruba","year":"2015","journal-title":"A Foniat"},{"key":"10.1016\/j.pupt.2018.10.005_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5414\/CPP38402","article-title":"A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine)","volume":"8","author":"Titti","year":"2000","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"10.1016\/j.pupt.2018.10.005_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5414\/CPP45016","article-title":"Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children","volume":"1","author":"Balli","year":"2007","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"10.1016\/j.pupt.2018.10.005_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pupt.2009.10.002","article-title":"The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a metha-analysis of individual patient data","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2018.10.005_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.pupt.2017.11.009","article-title":"Impact of erdosteine on chronic bronchitis and CODP: a meta-analysis","volume":"48","author":"Cazzola","year":"2018","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2018.10.005_bib16","doi-asserted-by":"crossref","first-page":"1700711","DOI":"10.1183\/13993003.00711-2017","article-title":"Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study","volume":"50","author":"Dal Negro","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.pupt.2018.10.005_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132670","article-title":"Comorbid influences on generic health-related quality of life in COPD: a systematic review","volume":"10","author":"Huber","year":"2015","journal-title":"PloS One"},{"issue":"5430","key":"10.1016\/j.pupt.2018.10.005_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/bmj.1.5430.317","article-title":"NAC and antibiotics in cystic fibrosis","volume":"1","author":"Lawson","year":"1965","journal-title":"Br. Med. J."},{"issue":"4","key":"10.1016\/j.pupt.2018.10.005_bib19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/jcp.19.4.313","article-title":"Some observations on the penetration of antibiotics through mucus in vitro","volume":"19","author":"Saggers","year":"1966","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.pupt.2018.10.005_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1128\/jcm.5.1.58-61.1977","article-title":"Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro","volume":"5","author":"Parry","year":"1977","journal-title":"J. Clin. Microbiol."},{"issue":"8","key":"10.1016\/j.pupt.2018.10.005_bib21","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1128\/AAC.00710-10","article-title":"N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility","volume":"54","author":"Goswami","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.pupt.2018.10.005_bib22","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1128\/AAC.01334-16","article-title":"Effect of high N-acetylcysteine concentrations on antibiotic activity against a large collection of respiratory pathogens","volume":"60","author":"Landini","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.pupt.2018.10.005_bib23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/thx.43.8.585","article-title":"Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis","volume":"43","author":"Ricevuti","year":"1988","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.pupt.2018.10.005_bib24","first-page":"612","article-title":"Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study)","volume":"33","author":"Marchioni","year":"1995","journal-title":"Int. J. Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.pupt.2018.10.005_bib25","first-page":"171","article-title":"Erdosteine or placebo combined with co-trimoxazole in the treatment of hypersecretive infectious bronchitis: a double blind clinical trial","volume":"12","author":"H\u00f6tzinger","year":"1991","journal-title":"Med Praxis"},{"key":"10.1016\/j.pupt.2018.10.005_bib26","first-page":"35","article-title":"Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment","volume":"4","author":"Mohanty","year":"2001","journal-title":"J. Clin. Res."},{"issue":"4","key":"10.1016\/j.pupt.2018.10.005_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-0773.2003.920407.x","article-title":"Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide","volume":"92","author":"Jang","year":"2003","journal-title":"Pharmacol. Toxicol."},{"issue":"11","key":"10.1016\/j.pupt.2018.10.005_bib28","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1211\/0022357001777414","article-title":"Protective effect of erdosteine against hypochlorous acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic lung inflammation in mice","volume":"52","author":"Hayashi","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.pupt.2018.10.005_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tox.2006.08.027","article-title":"Regulation of sepsis-induced apoptosis of pulmonary cells by posttreatment of erdosteine and N-acetylcysteine","volume":"228","author":"Demiralay","year":"2006","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.pupt.2018.10.005_bib30","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s10753-016-0393-4","article-title":"Anti-inflammatory effect of erdosteine in lipopolysaccharide-stimulated RAW 264.7 cells","volume":"39","author":"Park","year":"2016","journal-title":"Inflammation"},{"issue":"Suppl. 2","key":"10.1016\/j.pupt.2018.10.005_bib31","first-page":"89","article-title":"Erdosteine 900 mg\/day leads to substantial changes in blood ROS, e-NO and some chemotactic cytokines in human secretions of current smokers","volume":"171","author":"Dal Negro","year":"2005","journal-title":"Am. J. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.10.005_bib32","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: national heart, lung, and blood institute and world health organization global initiative for chronic obstructive lung disease (GOLD): executive summary","volume":"163","author":"Pauwels","year":"2001","journal-title":"Am. J. Respir. Care"},{"issue":"2","key":"10.1016\/j.pupt.2018.10.005_bib33","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1164\/ajrccm.153.2.8564092","article-title":"Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma","volume":"153","author":"Keatings","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.pupt.2018.10.005_bib34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.pupt.2007.07.004","article-title":"Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD","volume":"21","author":"Dal Negro","year":"2008","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2018.10.005_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pupt.2016.09.007","article-title":"Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: results of a placebo controlled trial","volume":"41","author":"Dal Negro","year":"2016","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2018.10.005_bib36","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.2147\/COPD.S87091","article-title":"Erdosteine reduces inflammation and time to first exacerbation post-discharge in hospitalized patients with AECOPD","volume":"10","author":"Moretti","year":"2015","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.pupt.2018.10.005_bib37","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2147\/COPD.S54475","article-title":"The causes and consequences of seasonal variation in COPD exacerbations","volume":"9","author":"Donaldson","year":"2014","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.pupt.2018.10.005_bib38","first-page":"457","article-title":"Utility of the immunoglobulin-like fold of chaperones in shaping organelles of attachment in pathogenesis bacteria","volume":"61","author":"Hultgren","year":"1995","journal-title":"ASM News"},{"issue":"2\u20133","key":"10.1016\/j.pupt.2018.10.005_bib39","first-page":"75","article-title":"The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone","volume":"28","author":"Dal Sasso","year":"2002","journal-title":"Drugs Exp. Clin. Res."},{"issue":"3","key":"10.1016\/j.pupt.2018.10.005_bib40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000063223","article-title":"Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone","volume":"47","author":"Braga","year":"2001","journal-title":"Chemotherapy"},{"issue":"1","key":"10.1016\/j.pupt.2018.10.005_bib41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/AAC.47.1.48-53.2003","article-title":"Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages","volume":"47","author":"Yamaryo","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.pupt.2018.10.005_bib42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/bbrc.1999.1917","article-title":"Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells","volume":"267","author":"Desaki","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.pupt.2018.10.005_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/ajrcmb.22.1.3400","article-title":"Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells","volume":"22","author":"Abe","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"6","key":"10.1016\/j.pupt.2018.10.005_bib44","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.rmed.2013.02.009","article-title":"Role of long term antibiotics in chronic respiratory diseases","volume":"107","author":"Suresh Babu","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2018.10.005_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-9255-5-11","article-title":"Anti-inflammatory effects of ciprofloxacin in S. aureus Newman induced nasal inflammation in vitro","volume":"5","author":"Sachse","year":"2008","journal-title":"J. Inflamm."},{"issue":"1","key":"10.1016\/j.pupt.2018.10.005_bib46","first-page":"1","article-title":"Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin","volume":"74","author":"Buret","year":"2010","journal-title":"Can. J. Vet. Res."},{"issue":"Suppl 2","key":"10.1016\/j.pupt.2018.10.005_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s15010-005-8209-8","article-title":"Immunomodulatory activities of fluoroquinolones","volume":"33","author":"Dalhoff","year":"2005","journal-title":"Infection"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553918301883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553918301883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:28:20Z","timestamp":1761082100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553918301883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":47,"alternative-id":["S1094553918301883"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2018.10.005","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2018.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}